stockrowAMNEAL PHARMACEUTICALS, INC.
AMRX Healthcare Drug Manufacturers Specialty & Generic
AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.
- Revenue
- +9.96%
- EPS
- +267.0%
- Free cash flow
- −50.9%
- Total debt
- +23.8%
Quarter to September 2026, against a year earlier
Follow AMRX
Alert me
AMNEAL PHARMACEUTICALS, INC. (AMRX) Operating cash flow
AMNEAL PHARMACEUTICALS, INC.'s operating cash flow for fiscal 2025 was $340.0M, up 15.2% from $295.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was $180.6M. Over the past ten years it has ranged from $1.7M (fiscal 2019) to $379.0M (fiscal 2020); the current reading is higher than 82% of that period. AMNEAL PHARMACEUTICALS, INC. ranks 22nd of 84 Drug Manufacturers Specialty & Generic companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $340.0M | 15.21% |
| FY2024 | $295.1M | (14.61%) |
| FY2023 | $345.6M | 430.84% |
| FY2022 | $65.1M | (73.08%) |
| FY2021 | $241.8M | (36.20%) |
| FY2020 | $379.0M | 22,128.80% |
| FY2019 | $1.7M | (99.32%) |
| FY2018 | $250.2M | 6.85% |
| FY2017 | $234.2M | 103.53% |
| FY2016 | $115.1M | 24.45% |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $98.3M | — |
| Jun 2026 | −$21.2M | — |
| Mar 2026 | −$26.7M | — |
| Dec 2025 | $130.3M | 10.02% |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| ELAN Elanco Animal Health Incorporated compare | $617.0M |
| LNTH Lantheus Holdings, Inc. compare | $409.5M |
| RDY Dr. Reddy's Laboratories Ltd compare | $313.0M |
| HIMS Hims & Hers Health, Inc. compare | $263.5M |
| ALKS Alkermes plc compare | $243.0M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $198.8M |
| AMRX AMNEAL PHARMACEUTICALS, INC. | $180.6M |
| LQDA Liquidia Corporation compare | $167.7M |
| SUPN Indivior Pharmaceuticals Inc. compare | $96.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on AMRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement